| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.11.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.11.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 12.11.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 12.11.2024ISIN NameCA74734T1049 PYROGENESIS... ► Artikel lesen | |
| 04.11.24 | Nasdaq Stockholm AB: Delisting of Deversify Health AB (publ) from Nasdaq First North Growth Market | On November 4, 2024, Deversify Health AB (publ) was declared bankrupt by
Uppsala District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the
exchange may decide to... ► Artikel lesen | |
| 01.11.24 | XFRA 9BX: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILDEVERSIFY HEALTH... ► Artikel lesen | |
| 25.09.24 | Nasdaq Stockholm AB: New equity right for trading, Deversify Health AB (publ) | At the request of Deversify Health AB (publ), equity rights will be traded on
First North as from 26 September 2024.
TO3
Security name: DEVERSIFY HEALTH TO 3
-------------------------------------
Short... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.02. | TC BioPharm: TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial | No adverse events related to TCB008 have occurred
Evidence of stable disease following TCB008 infusion
EDINBURGH, Scotland, Feb. 13, 2025 /PRNewswire/ --... ► Artikel lesen | |
| 10.02. | TC BioPharm plc - 6-K, Report of foreign issuer | ||
| 10.02. | TC BioPharm vermeldet Fortschritte bei AML-Behandlungsstudie | ||
| 10.02. | TC BioPharm: TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial | First Cohort B patient received 4 doses (approx. 819 million Gamma Delta T-cells)
Cohort B recruitment continues at multiple clinical sites across the United... ► Artikel lesen | |
| 10.02. | EXCLUSIVE: Nano-Cap TC BioPharm Concludes Initial Cohort B Patient Dosing In Mid-Stage Leukemia Trial, Data Readout By End Of 2025 |
| Unternehmen / Aktien | Kurs | % |
|---|---|---|
| DEVERSIFY HEALTH AB | 0,000 | 0,00 % |
| TC BIOPHARM HOLDINGS PLC ADR | 1,970 | 0,00 % |
